As part of complex therapy. In adults: chronic heart failure, dilated cardiomyopathy, coronary heart disease, including myocardial infarction (during rehabilitation therapy), arrhythmias, arterial hypertension. In children from 1 year old: chronic heart failure, dilated cardiomyopathy, arrhythmias, chronic gastroduodenitis, chronic pyelonephritis, metabolic nephropathy, migraine, neurocirculatory dystonia, hereditary neurodegenerative diseases (mitochondrial encephalomyopathy (MELAS syndrome), Leig's syndrome, tuberous sclerosis), congenital myopathies, muscular dystrophies, diseases associated with metabolic disorders (asthenic syndrome, recovery period after serious illnesses and surgical interventions). The period of preparation for heart surgery (coronary bypass grafting, congenital and acquired defects) in adults and children from 1 year old on the recommendation of a doctor. To improve adaptation to increased physical activity in adults and children from 1 year old. For the prevention and replenishment of coenzyme Q10 deficiency in adults and children from 1 year of age.

Hypersensitivity to the components of the drug. Children's age up to 1 year.

The drug should be taken orally 1 time per day during a meal in the first half of the day, previously dissolved in a small amount of boiled water or another drink at room temperature. In order to prevent and compensate for coenzyme Q10 deficiency, take in accordance with the recommendations: Children from 1 to 3 years old, 2-4 drops each Children from 3 to 7 years old, 4-8 drops each Children from 7 to 12 years old, 8-12 drops each Children over 12 years old and adults 12-24 drops each In the complex therapy of various diseases, Kudesan should be taken depending on age for all the stated indications in accordance with the recommendations: Children from 1 to 3 years old, 4-10 drops each Children from 3 to 7 10-16 drops each Children from 7 to 12 years old 16-20 drops each Children over 12 years old and adults 20-60 drops each The duration of the Kudesan course is 2-3 months. Repeated courses - on the recommendation of a doctor.

Simultaneous use of lipid-lowering drugs (statins, fibrates), beta-blockers (atenolol, metoprolol, propranolol), tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in blood plasma. Ubidecarenone may potentiate the action of diltiazem, metoprolol, enalapril, and nitrates, as well as reduce the action of warfarin.

With caution: with arterial hypotension. The drug is not recommended for pregnant and lactating women due to the lack of sufficient clinical experience.

Qudesan is more effective than external agents in providing the skin with this essential substance for its health. Positive effect in coronary heart disease and other diseases of the cardiovascular system, prevention and treatment of atherosclerosis and its complications, especially hypertension.

It has a cardiotonic, cardioprotective, adaptogenic and immunostimulating effect. Promotes the restoration of physical performance, increases the ability of the body to adapt to increased stress, stress and hypoxia.

Indications for use as part of complex therapy:

In adults: chronic heart failure, dilated cardiomyopathy, coronary heart disease, including myocardial infarction (during rehabilitation therapy), arrhythmias, arterial hypertension.

Studies have shown that the bioavailability of coenzyme Q10 in the composition of Qudesan is 2.5 times higher than when using conventional, fat-soluble forms of coenzyme. And higher bioavailability provides greater effectiveness.

The presence of Q10 in all cells and natural origin ensure the safety of Qudesan. There are also no negative drug interactions. In the production of Qudesan, a unique microencapsulation technology developed and patented by Russian scientists is used.

It has been proven that the use of Qudesan in combination with traditional antihypertensive therapy contributed to the normalization of the function of the vascular endothelium, more effective correction of the daily blood pressure profile, which indicates the prospects for the use of Qudesan in complex treatment.